Dec 11, 2023
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
Nov 09, 2023
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
Nov 01, 2023
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
Sep 06, 2023
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
Aug 30, 2023
Tarsus to Present at Upcoming Investor Conferences
Aug 24, 2023
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
Aug 10, 2023
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
Aug 01, 2023
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
Jul 31, 2023
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
Jul 25, 2023
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
Displaying 1 - 10 of 18